

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
29 June 2006 (29.06.2006)

PCT

(10) International Publication Number  
**WO 2006/066891 A3**

(51) International Patent Classification:

A61K 47/48 (2006.01)

(21) International Application Number:

PCT/EP2005/013756

(22) International Filing Date:

21 December 2005 (21.12.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

04030415.6 22 December 2004 (22.12.2004) EP

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4002 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **AMREIN, Beat** [CH/CH]; Allmendstrasse 89, CH-4497 Ruenenberg (CH). **FOSER, Stefan** [DE/DE]; Granatgässle 7b, 79102 Freiburg i. Brg. (DE). **LANG, Kurt** [DE/DE]; Langoner Strasse 10, 82377 Penzberg (DE). **METZGER, Friedrich** [DE/DE]; Am Kirchacker 45, 79115 Freiburg (DE). **REGULA, Jörg** [DE/DE]; Lierstrasse 15, 80639 München (DE). **SCHAUBMAR, Andreas** [DE/DE]; Reindl 38, 82377 Penzberg (DE). **HESSE, Friederike** [DE/DE]; Ganghoferstrasse 23, 80339 München (DE). **KUENKELE, Klaus-Peter** [DE/DE]; Karwendelstrasse 9, 83671 Benediktbeuern (DE). **LANZENDOERFER, Martin** [DE/DE]; Hofmairstrasse 25a, 82327 Tutzing (DE).

(74) Agent: **BRAUN, Axel**; F. Hoffmann-La Roche AG, Patent Department (CLP), Postfach 3255, CH-4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declaration under Rule 4.17:**

— of inventorship (Rule 4.17(iv))

**Published:**

— with international search report  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:  
31 May 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CONJUGATES OF INSULIN-LIKE GROWTH FACTOR-1 (IGF-1) AND POLY(ETHYLENE GLYCOL)

(57) Abstract: A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.



WO 2006/066891 A3